Redistribution of vertebral bone mineral density after transient administration of recombinant human PTH(1-34), LY333334, in monkeys

被引：0
|
作者：
Turner, CH [1 ]
Hannum, B [1 ]
Gurdogan, O [1 ]
Clendenon, J [1 ]
Sato, M [1 ]
机构：
[1] Indiana Univ, Lilly Res Labs, Indianapolis, IN 46204 USA
来源：
SIROT 99 | 1999年
关键词：
D O I：
暂无
中图分类号：
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];
学科分类号：
摘要：
引用
收藏
页码：721 / 724
页数：4
相关论文
共 50 条
  • [1] Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys
    Brommage, R
    Hotchkiss, CE
    Lees, CJ
    Stancill, MW
    Hock, JM
    Jerome, CP
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10): : 3757 - 3763
  • [2] In monkeys, treatment with PTH(1-34), LY333334, increases bone strength in lumbar vertebrae and the femoral neck without compromising cortical bone strength
    Turner, CH
    Wang, T
    Hirano, T
    Burr, DB
    Hock, JM
    Hotchkiss, CE
    Brommage, R
    Jerome, CP
    [J]. SIROT 99, 1999, : 107 - 110
  • [3] In primates, treatment with PTH (1-34), LY333334, increases bone strength at trabecular bone sites without compromising the strength of cortical bone.
    Turner, CH
    Wang, T
    Hirano, T
    Burr, DB
    Hock, JM
    Hotchkiss, CE
    Brommage, R
    Jerome, CP
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S414 - S414
  • [4] In vivo and in vitro comparison of LY333334, biosynthetic human parathyroid hormone (hPTH) (1-34), with synthetic hPTH(1-34).
    Black, EC
    Frolik, CA
    Hock, JM
    Cain, RL
    Chandrasekhar, S
    Harvey, AK
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : F370 - F370
  • [5] Effects of LY333334 [recombinant human parathyroid hormone (1-34)] and alendronate sodium on markers of bone metabolism in postmenopausal women with osteoporosis.
    Body, JJ
    Gaich, GA
    Scheele, WH
    Kulkarni, PM
    Hodsman, AB
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S530 - S530
  • [6] Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-Related protein (1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats
    Frolik, CA
    Cain, RL
    Sato, M
    Harvey, AK
    Chandrasekhar, S
    Black, EC
    Tashjian, AH
    Hock, JM
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (02) : 163 - 172
  • [7] Comparison of dose, drug concentrations, and biochemical markers of bone turnover as predictors of bone mineral density response to LY333334 [rhPTH(1-34)] in women with osteoporosis.
    Satterwhite, JH
    Melnick, KA
    O'Brien, LM
    Gaich, GA
    Heathman, MA
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S230 - S230
  • [8] Assessment of effects of LY333334 [recombinant human parathyroid hormone (1-34)] on cortical bone using digital X-ray radiogrammetry.
    Hyldstrup, L
    Jorgensen, JT
    Gaich, G
    [J]. BONE, 2001, 28 (05) : S97 - S98
  • [9] Early effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling and mechanical properties of cortical bone in rabbits
    Mashiba, T
    Burr, DB
    Turner, CH
    Sato, M
    Cain, RL
    Hock, JM
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (04) : 804 - 804
  • [10] Effects of baseline BMD, age, and prevalent vertebral fractures on the response of osteoporotic patients to LY333334 [rhPTH(1-34)].
    Marcus, R
    Gaich, GA
    Satterwhite, JH
    Myers, SL
    Wang, O
    Mitlak, BH
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S194 - S194
12345